tiprankstipranks
Advertisement
Advertisement

GHRS Stock Latest News

Psychedelic: Compass Pathways, NRx Pharma report earnings results
The FlyPsychedelic: Compass Pathways, NRx Pharma report earnings results
19d ago
ATAI
CMPS
GH Research Publishes Phase 2b GH001 TRD Data and Highlights Severity-Independent Efficacy
PremiumCompany Announcements
GH Research Publishes Phase 2b GH001 TRD Data and Highlights Severity-Independent Efficacy
20d ago
6K
GHRS
GH Research announces publication of Phase 2b results for mebufotenin
PremiumThe Fly
GH Research announces publication of Phase 2b results for mebufotenin
20d ago
GHRS
GH Research to Join Stifel 2026 Virtual CNS Forum Fireside Chat
PremiumCompany Announcements
GH Research to Join Stifel 2026 Virtual CNS Forum Fireside Chat
29d ago
6K
GHRS
GH Research: Advancing GH001 Toward 2026 Pivotal Phase 3 in Treatment-Resistant Depression With Favorable Risk-Reward and $70 Target
PremiumRatings
GH Research: Advancing GH001 Toward 2026 Pivotal Phase 3 in Treatment-Resistant Depression With Favorable Risk-Reward and $70 Target
1M ago
GHRS
Psychedelic: Clearmind advances recruitment for CMND-100 trial’s third cohort
PremiumThe FlyPsychedelic: Clearmind advances recruitment for CMND-100 trial’s third cohort
1M ago
ATAI
CMND
GH Research price target raised to $34 from $29 at Guggenheim
Premium
The Fly
GH Research price target raised to $34 from $29 at Guggenheim
1M ago
GHRS
GH Research: Advancing Phase 3 TRD Program Post‑Hold with Strong Cash Runway Supports Buy Rating
Premium
Ratings
GH Research: Advancing Phase 3 TRD Program Post‑Hold with Strong Cash Runway Supports Buy Rating
1M ago
GHRS
GH Research price target raised to $42 from $39 at Citizens
PremiumThe Fly
GH Research price target raised to $42 from $39 at Citizens
1M ago
GHRS
GH Research: Phase 3 Readiness, Expanding Indications, and Valuation Upside Reinforce Buy Rating
PremiumRatings
GH Research: Phase 3 Readiness, Expanding Indications, and Valuation Upside Reinforce Buy Rating
1M ago
GHRS
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
PremiumThe Fly
Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
1M ago
PBM
ATAI
GH Research Posts 2025 Results as TRD Drug GH001 Clears Key Phase 2b Milestone
PremiumCompany Announcements
GH Research Posts 2025 Results as TRD Drug GH001 Clears Key Phase 2b Milestone
1M ago
6K
GHRS
GH Research reports FY25 EPS (79c), consensus (82c)
PremiumThe FlyGH Research reports FY25 EPS (79c), consensus (82c)
1M ago
GHRS
Psychedelic: Analyst raises Compass, Definium, GH Research price targets
Premium
The Fly
Psychedelic: Analyst raises Compass, Definium, GH Research price targets
3M ago
PBM
CMPS
GH Research price target raised to $40 from $33 at RBC Capital
Premium
The Fly
GH Research price target raised to $40 from $33 at RBC Capital
3M ago
GHRS
GH Research to Present at RBC Capital Markets Psychedelics Symposium
PremiumCompany Announcements
GH Research to Present at RBC Capital Markets Psychedelics Symposium
3M ago
6K
GHRS
GH Research Showcases GH001 Depression Data at ACNP 2026 Mini‑Panel
PremiumCompany Announcements
GH Research Showcases GH001 Depression Data at ACNP 2026 Mini‑Panel
3M ago
6K
GHRS
GH Research Showcases Positive GH001 Phase 2b Data in Treatment-Resistant Depression at ACNP 2026
PremiumCompany Announcements
GH Research Showcases Positive GH001 Phase 2b Data in Treatment-Resistant Depression at ACNP 2026
3M ago
6K
GHRS
Psychedelic: Bright Minds reports results from Phase 2 BMB-101 trial
PremiumThe Fly
Psychedelic: Bright Minds reports results from Phase 2 BMB-101 trial
3M ago
CMPS
DRUG
GH Research to Present Six-Month Safety and Efficacy Data on Inhaled GH001 in Depression at 2026 ACNP Meeting
PremiumCompany AnnouncementsGH Research to Present Six-Month Safety and Efficacy Data on Inhaled GH001 in Depression at 2026 ACNP Meeting
3M ago
6K
GHRS
GH Research price target raised to $29 from $19 at Needham
Premium
The Fly
GH Research price target raised to $29 from $19 at Needham
3M ago
GHRS
GH Research price target raised to $39 from $35 at Canaccord
Premium
The Fly
GH Research price target raised to $39 from $35 at Canaccord
3M ago
GHRS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >